Pharmacogenetic-guided warfarin dosing algorithm in African-Americans

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 1, 2016, Pages 86-92

  Alzubiedi, Sameh ^a   Saleh, Mohammad I ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

African American; artificial neural network; individulaization; pharmacogenomics; rs12777823; warfarin dosing

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; WARFARIN; CYP2C9 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL NEURAL NETWORK; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; AGED; COHORT ANALYSIS; DOSE RESPONSE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PROCEDURES;

ADULT; AFRICAN AMERICANS; AGED; ALGORITHMS; COHORT STUDIES; CYTOCHROME P-450 CYP2C9; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 84954558622     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000317     Document Type: Article

References (57)

1. Siguret V, Pautas E, Gouin-Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam Horm. 2008;78:247-264.
2. Saleh MI. Clinical predictors associated with warfarin sensitivity [published online March 27, 2015]. Am J Ther. 2015. doi:10.1097/MJT. 0000000000000248.
3. Kimmel SE. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008;9:677-686.
4. Kamali F. Genetic influences on the response to warfarin. Curr Opi Hematol. 2006;13:357-361.
5. Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res. 2007;5:8-16.
6. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63:1135-1141.
7. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106:2329-2333.
8. El Rouby S, Mestres CA, LaDuca FM, et al. Racial and ethnic differences in warfarin response. J Heart Valve Dis. 2004;13:15-21.
9. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008-1012.
10. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol. 2006;61:746-751.
11. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007;8:851-861.
12. Saleh MI, Alzubiedi S. Dosage individualization of warfarin using artificial neural networks. Mol Diagn Ther. 2014;18:371-379.
13. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.
14. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-2570.
15. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012;13:407-418.
16. Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics. 2004;14:539-547.
17. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
18. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
19. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans. Clin Pharmacol Ther. 2008;84:332-339.
20. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008;9:511-526.
21. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827-3834.
22. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382:790-796.
23. Roper N, Storer B, Bona R, et al. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn. 2010;12:283-291.
24. Zhao L, Chen C, Li B, et al. Verification of pharmacogenetics-based warfarin dosing algorithms in Han Chinese patients undertaking mechanic heart valve replacement. PLoS One. 2014;9:e94573.
25. Saleh MI, Alzubiedi S. Dosage individualization of warfarin using artificial neural networks. Mol Diagn Ther. 2014;18:371-379.
26. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-4112.
27. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10:261-266.
28. Hirai K, Hayashi H, Ono Y, et al. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug Metab Pharmacokinet. 2013;28:132-137.
29. Cen HJ, Zeng WT, Leng XY, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010;70:234-240.
30. McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75:1337-1346.
31. Edson KZ, Prasad B, Unadkat JD, et al. Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry. 2013;52:8276-8285.
32. Lee KE, Chang BC, Kim HO, et al. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit. 2012;34:275-282.
33. Nakamura K, Obayashi K, Araki T, et al. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther. 2012;37:481-485.
34. Stats D, Davison S. The increased hypoprothrombinemic effect of a small dose of dicumarol in congestive heart failure. Am J Med Sci. 1949;218: 318-323.
35. Reisner EH Jr, Norman J, Field WW, et al. The effect of liver dysfunction on the response to dicumarol. Am J Med Sci. 1949;217:445-447.
36. Visser LE, Bleumink GS, Trienekens PH, et al. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004;127:85-89.
37. Killip T III, Payne MA. High serum transaminase activity in heart disease. Circulatory failure and hepatic necrosis. Circulation. 1960;21:646-660.
38. Demirkan K, Stephens MA, Newman KP, et al. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J. 2000;93: 448-454; quiz 55.
39. Miura T, Nishinaka T, Terada T, et al. Relationship between aging and dosage of warfarin: the current status of warfarin anticoagulant therapy for Japanese outpatients in a department of cardiovascular medicine. J Cardiol. 2009;53:355-360.
40. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size, and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol. 1995;40:203-207.
41. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;116:901-904.
42. Shepherd AM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4:315-320.
43. Lurie Y, Loebstein R, Kurnik D, et al. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol. 2010;70:164-170.
44. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(1 suppl):8S-21S.
45. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165:1095-1106.
46. Chen LY, Eriksson N, Gwilliam R, et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood. 2005;106:3673-3674.
47. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-2635.
48. Kimmel SE, Christie J, Kealey C, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African-Americans. Pharmacogenomics J. 2008;8:53-60.
49. Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005;93: 872-875.
50. Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol. 2011;154:311-324.
51. Myatt GJ, Johnson WP. Making sense of data II: a practical guide to data visualization, advanced data mining methods, and applications. Choice AND Curr Rev Acad Libraries. 2009;47:345-346.
52. Sivanandam SN, Deepa SN. Introduction to Neural Networks Using Matlab 6.0. New Delhi, India: Tata McGraw-Hill Education; 2006.
53. Yamamura S, Kawada K, Takehira R, et al. Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients. Biomed Pharmacother. 2004;58:239-244.
54. Gaweda AE, Jacobs AA, Brier ME, et al. Pharmacodynamic population analysis in chronic renal failure using artificial neural networks-a comparative study. Neural Netw. 2003;16:841-845.
55. Kim YS, Sohn SY, Kim DK, et al. Screening test data analysis for liver disease prediction model using growth curve. Biomed Pharmacother. 2003;57:482-488.
56. Camps-Valls G, Porta-Oltra B, Soria-Olivas E, et al. Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks. IEEE Trans Biomed Eng. 2003;50:442-448.
57. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African-Americans. Pharmacogenomics J. 2014;14:223-228.